Published February 2017. This article examines the policy and commercial implications of the Trump administration's stance on vaccines and the broader dynamics of vaccine hesitancy in the US market.
The Anti-Vaccine Movement Before Trump
Most observers are aware that the new US president, Donald Trump, had made erroneous claims that vaccines cause autism. But even before Trump's inauguration the anti-vaccine movement had already caused considerable damage to an important public health programme. One US survey indicated that one in ten Americans believes vaccines are not safe, and 30% of respondents said parents should be able to decide not to vaccinate their children. Such beliefs are now responsible for a resurgence in childhood diseases once under control: in 2015, the CDC reported ten times the number of measles cases (667) compared to 2010.
Americans who believe vaccines are not safe, according to a Pew Research Center survey. 30% of respondents believed parents should be able to decide not to vaccinate their children.
Why Vaccine Hesitancy Persists
The vaccine-autism story, initiated by the retracted 1998 Lancet article by Andrew Wakefield, has been disproved on many occasions by reputable bodies studying thousands more children than the original twelve. There is still no scientific evidence that vaccines cause autism. The movement persists for complex, interconnected reasons, not least that a proportion of the public distrust central government decisions. High-profile individuals - celebrities and politicians - have amplified this current, whether or not they believe the underlying science.
The vaccine industry has also experienced its share of setbacks: the withdrawal of RotaShield (1999), Guillain-Barré syndrome associations with the 1976 swine flu campaign, narcolepsy and Pandemrix during the 2009 H1N1 pandemic, and the low effectiveness of the 2014-15 seasonal influenza vaccine. Conspiracy theorists cite each example as evidence that powerful companies force dangerous vaccines on an unwitting public.
The Regulatory and Political Environment
President Trump appointed Tom Price to head the US Department of Health and Human Services. Price, a Republican and former surgeon, should understand evidence-based policy, though much of his anticipated focus was on rolling back the Affordable Care Act. Groups attempting to pin down Price on his attitudes to vaccines found him non-committal, though news articles suggested he believed vaccines have 'an important role in public health'. More concrete concerns centred on potential cuts to Section 317 federal vaccine funding, worth approximately $600m per year.
"Bacteria, viruses, and parasites don't listen to politicians. They kill indiscriminately."
Industry Risk Mitigation
For many years, the vaccine industry has been conscious of paediatric "schedule crowding" and perceived safety concerns. Moves towards combination products, removal of preservatives, and intranasal delivery have all sought to reduce parental fear. Strategies for RSV and Group B Streptococcus seek to protect infants by vaccinating the mother. To some extent, risk has already been diversified: companies now have portfolios focused on vaccines for adolescents, adults, and the elderly, where autism concerns are less relevant. For existing US paediatric sales - a significant proportion of yearly revenues - one can only hope that evidence-based reasoning prevails.
This article is available in VacZine Analytics' Expert News archive as published in February 2017.